MOXATAG (amoxicillin) by Pragma Bio is drug. First approved in 2008.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
MOXATAG is an extended-release oral tablet formulation of amoxicillin, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. It is indicated for treatment of bacterial infections susceptible to amoxicillin. The extended-release mechanism allows for reduced dosing frequency compared to immediate-release formulations.
Product faces imminent generic erosion with 0.6 years of exclusivity remaining; commercial teams should anticipate workforce optimization and transition to defensive positioning or pipeline acceleration.
drug. [see Clinical Pharmacology ()]
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin
A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin
Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection
Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
Worked on MOXATAG at Pragma Bio? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
MOXATAG offers minimal career growth opportunity given its imminent loss of exclusivity and zero linked job openings. Professionals joining the brand team should expect a defensive, cost-optimization mandate rather than expansion or innovation-focused work. This product is suited for experienced leaders managing portfolio contraction or early-career professionals seeking antibiotic/primary care market exposure before transitioning to growth-stage assets.